Related Experiment Videos
Intravesical epirubicin treatment following TUR in superficial bladder tumours
M A Imamoğlu1, H Bakirtaş, O Yiğitbaşi
1S.S.K. Ankara Hospital 1, Urology Clinic, Ankara, Turkey. mai2603@superonline.com
Objective:
To evaluate the effectiveness and tolerability of intravesical epirubicin treatment to prevent recurrence and progression of superficial bladder tumor after TUR.
Methods:
44 patients with superficial bladder tumor, 28 primary and 16 recurrent cases were given 50 mg intravesical epirubicin once a week for 8 weeks after TUR. Recurrent cases had not been treated by any intravesical agent before. Follow-up was done by cystoscopy, urine cytology and random biopsies.
Results:
Local recurrence after treatment was found in 14.28% and 18.75%, and recurrence in another area was found in 21.42% and 31.25% of the primary and recurrent tumor groups respectively. Total recurrence in both groups was 40.91%. No systemic toxicity was observed and local side effects were treated symptomatically.
Conclusion:
Intravesical epirubicin after TUR for superficial bladder tumors especially for the primary ones, is a reliable method that provides effective prophylaxis with tolerable side effects.